Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Regulus Therapeutics (RGLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 20,301
  • Shares Outstanding, K 20,548
  • Annual Sales, $ 70 K
  • Annual Income, $ -48,710 K
  • 60-Month Beta 2.03
  • Price/Sales 276.77
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.60
  • Number of Estimates 2
  • High Estimate -0.30
  • Low Estimate -0.89
  • Prior Year -1.56
  • Growth Rate Est. (year over year) +61.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.90 +31.46%
on 06/07/19
1.47 -19.56%
on 05/22/19
+0.02 (+1.72%)
since 05/17/19
3-Month
0.90 +31.46%
on 06/07/19
1.62 -27.14%
on 05/14/19
+0.06 (+5.36%)
since 03/18/19
52-Week
0.80 +47.50%
on 12/24/18
9.00 -86.89%
on 07/05/18
-7.10 (-85.75%)
since 06/18/18

Most Recent Stories

More News
Regulus Announces New Additions to Board of Directors

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Jake Nunn and Simos Simeonidis,...

RGLS : 1.18 (+19.43%)
Watch for Regulus Therapeu to Potentially Pullback After Gaining 7.86% Yesterday

Regulus Therapeu (NASDAQ:RGLS) traded in a range yesterday that spanned from a low of $1.51 to a high of $1.59. Yesterday, the shares gained 7.9%, which took the trading range above the 3-day high of...

RGLS : 1.18 (+19.43%)
Regulus Therapeutics Reports First Quarter 2019 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial...

RGLS : 1.18 (+19.43%)
Regulus Therapeutics Announces Closing of First Tranche of $41.8 Million Private Placement of Equity

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the closing of the first tranche...

RGLS : 1.18 (+19.43%)
Regulus Therapeutics Announces Restructuring of Term Loan

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has entered into an amendment...

RGLS : 1.18 (+19.43%)
Regulus Therapeutics Announces Private Placement of Equity

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it has entered into a definitive...

RGLS : 1.18 (+19.43%)
Recent Analysis Shows Regulus Therapeutics, Limbach, CytRx, and Rand Capital Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Regulus Therapeutics Inc. (NASDAQ:RGLS),...

LMB : 8.76 (+1.39%)
RAND : 2.76 (-2.57%)
LMBH : 15.6700 (+4.47%)
RGLS : 1.18 (+19.43%)
CYTR : 0.3600 (+2.86%)
Regulus to Present Preclinical Efficacy Data Highlighting Potential of Novel Treatment for Nonalcoholic Steatohepatitis at The International Liver Congress(TM) 2019

Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced that it will present preclinical...

RGLS : 1.18 (+19.43%)
Regulus Therapeu Set to Possibly Rebound After Yesterday's Selloff of 1.97%

Regulus Therapeu (NASDAQ:RGLS) traded in a range yesterday that spanned from a low of $0.98 to a high of $1.01. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $1.00...

RGLS : 1.18 (+19.43%)
Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates

Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth...

RGLS : 1.18 (+19.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft. Long term indicators fully support a continuation of the trend.

See More Share

Trade RGLS with:

Business Summary

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and...

See More

Key Turning Points

2nd Resistance Point 1.44
1st Resistance Point 1.31
Last Price 1.18
1st Support Level 1.01
2nd Support Level 0.83

See More

52-Week High 9.00
Fibonacci 61.8% 5.87
Fibonacci 50% 4.90
Fibonacci 38.2% 3.93
Last Price 1.18
52-Week Low 0.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar